UK Markets close in 8 hrs 9 mins
  • FTSE 100

    7,561.07
    +39.68 (+0.53%)
     
  • FTSE 250

    19,082.68
    -17.40 (-0.09%)
     
  • AIM

    838.90
    -1.29 (-0.15%)
     
  • GBP/EUR

    1.1604
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2133
    -0.0000 (-0.0024%)
     
  • BTC-GBP

    13,827.20
    -270.56 (-1.92%)
     
  • CMC Crypto 200

    393.72
    -8.08 (-2.01%)
     
  • S&P 500

    3,941.26
    -57.58 (-1.44%)
     
  • DOW

    33,596.34
    -350.76 (-1.03%)
     
  • CRUDE OIL

    73.87
    -0.38 (-0.51%)
     
  • GOLD FUTURES

    1,783.70
    +1.30 (+0.07%)
     
  • NIKKEI 225

    27,686.40
    -199.47 (-0.72%)
     
  • HANG SENG

    18,852.16
    -589.02 (-3.03%)
     
  • DAX

    14,313.42
    -29.77 (-0.21%)
     
  • CAC 40

    6,690.27
    +2.48 (+0.04%)
     

Vita 34 benefits from increasing normalization in its core business in the third quarter

EQS-News: Vita 34 AG / Key word(s): 9 Month figures
Vita 34 benefits from increasing normalization in its core business in the third quarter
22.11.2022 / 15:51 CET/CEST
The issuer is solely responsible for the content of this announcement.

Vita 34 benefits from increasing normalization in its core business in the third quarter

  • Revenues for the first nine months rose to EUR 50.8 million; business development gains further momentum in the third quarter

  • EBITDA of EUR -1.6 million in the first nine months below previous year due to continued investments in the new activities, but already clearly positive again in the third quarter

  • Outlook for the full year 2022 confirmed

Leipzig, 22 November 2022 - Against the backdrop of a still difficult economic environment, Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and third largest in the world, continues to lag behind its potential in its development so far in the current fiscal year. At the same time, however, there were signs of a further normalization of business development in the third quarter, accompanied by a noticeable improvement in the revenue and earnings situation at quarterly level.

As a result of the merger with PBKM FamiCord, revenues in the first nine months were again significantly higher than in the previous year at EUR 50.8 million (9M 2021: EUR 16.1 million). In contrast to the restrained business development in the first half of 2022, which was largely characterized by a clearly perceptible decline in demand from new customers as a result of the Omicron wave and the Ukraine conflict, the normalization of business development that had been apparent since June continued in the third quarter. Earnings before interest, taxes, depreciation and amortization (EBITDA) were still significantly lower year-on-year at EUR -1.6 million (9M 2021: EUR 3.1 million), partly due to further investments in the newly emerging activities and in R&D. However, against the backdrop of the resurgence in business development and lower cost of sales due to strict cost control, EBITDA in the third quarter was already back in clearly positive territory at EUR 1.0 million, although not yet at the level of the comparable period of the previous year (Q3 2021: EUR 1.5 million).

"2022 is without question a tough year for us. The restrictions imposed by COVID-19 and Russia's attack on Ukraine, which caused energy prices and inflation to rise abruptly, have acted as a psychological brake on signing a contract for many of our potential customers," says Jakub Baran, CEO of Vita 34 AG. "The new cost pressure on living expenses is very real for many of our customers. Therefore, it is only understandable that expectant parents first have to get used to the new spending levels until they can again mentally consider the unique opportunity that stem cell storage offers at the birth of their child. This normalization of demand is slowly emerging, but it appears to be sustainable."

The key figures for business development are as follows:

 

IFRS, in EUR ´000

Q3

Q3

9M

9M

9M

 

 

 

2022

2021*

2022

2021*

 

 

Revenues

18,655

5,646

50,764

16,111

215.1%

 

 

Gross profit

5,987

3,404

13,409

9,419

42.4%

 

 

EBITDA

1,008

1,486

-1,606

3,137

-151.2%

 

 

EBITDA margin [%]

5.4%

26.3%

-3.2%

19,5%

 

 

 

EBIT

-1,111

828

-7,976

954

-936.0%

 

 

Result for the period

-386

444

-8,058

132

-6,188,9%

 

 

Earnings per share [in EUR]

-0.02

0.11

-0.50

0.03

-1,766,7%

 

 

Operating cash flow

--

--

-3,219

2,390

-289.3%

 

 

Cash & cash equivalents
(vs. 31 Dec. 2021)

--

--

19,804

33,298

-40.5%

 

 

*Prior-year figures adjusted. The adjustments are explained in Note 2.3 of the Annual Report 2021.

 

 

Development progress in the new expanding Cell & Gene Therapies and CDMO business units still fell short of expectations. As the sales contribution of the units was still in the low single-digit million euro range and thus below expectations the company decided to slow down the scale of investments both on CAPEX and OPEX side.

"In our new business units, too, we are currently having to pay tribute to the distortions in the general economic environment. Almost all project steps are currently subject to delays”, Jakub Baran continues. "By means of strict cost discipline, we are at least managing to keep our expenses in check. And we are working hard to push the further progress of the project despite all adversities."

The Company has brought the necessary measures in connection with the harmonization of accounting under IFRS 15 to a positive conclusion. The negative effect from the impact of IFRS 15 amounted to EUR 2.5 million in the third quarter and thus to a total of EUR 6.5 million in the first nine months of 2022. "We have now implemented the relevant adjustments in most of the countries in our new contracts in a legally secure manner. This will then have a full positive impact on our accounting from the coming financial year onwards," summarizes Dirk Plaga, CFO of Vita 34 AG.

In view of the current business development and the expected further development in the remainder of the financial year, the Executive Board confirms the current forecast for the full year 2022, which provides for ranges of EUR 65 to 72 million for consolidated sales and EUR -6.0 to -3.0 million for EBITDA.

Contact:
Ingo Middelmenne
Investor Relations
Vita 34 AG
Phone: +49 (0341) 48792 - 0
Mobile: +49 (0174) 9091190
E-Mail: ingo.middelmenne@vita34.de

Company profile

Vita 34 was founded in Leipzig in 1997 and is today by far the leading cell bank in Europe and the third largest worldwide. As the first private cord blood bank in Europe and a pioneer in cell banking, the company has since been offering collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissue as a full-service provider for cryopreservation. Customers from around 50 countries have already provided for the health of their family with more than 850,000 units of stored biological materials at Vita 34.


22.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:

English

Company:

Vita 34 AG

Deutscher Platz 5a

04103 Leipzig

Germany

Phone:

+49(0341)48792-40

Fax:

+49(0341)48792-39

E-mail:

ir@vita34.de

Internet:

www.vita34.de

ISIN:

DE000A0BL849

WKN:

A0BL84

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1492745


 

End of News

EQS News Service

show this
show this